Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D’An to its Board of ...

Quantum BioPharma Ltd (NASDAQ:QNTM) shares are rising Tuesday after the company announced positive clinical trial results for ...

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

BioSpace Senior Editor Annalee Armstrong headed to the J.P. Morgan Healthcare Conference with a months-long story idea ...

RedHill Biopharma has begun a trial to assess the combination of opaganib and darolutamide for metastatic castrate-resistant ...

Zenas BioPharma (ZBIO) announced its 2024 accomplishments, outlined its key business objectives for 2025 and announced preliminary unaudited ...

Zenas BioPharma, Inc.’s ZBIO share price has surged by 13.37%, which has investors questioning if this is right time to sell.

CEO Kim Kelderman highlighted 9% organic revenue growth for the quarter, driven by strong performance in biopharma end markets, particularly large pharma, which benefited GMP reagents and protein ...

In an interview with ACT Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, discusses the "Choosing the Right Allies: ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Zenas BioPharma (NasdaqGS:ZBIO) with a ...